Innovent Announces the NMPA Approval of SINTBILO® (Tafo

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Related Keywords

China , United States , Peking , Beijing , Suzhou , Jiangsu , Taiwan , Hong Kong , Macau , Chinese , Yong Huo , Eli Lilly , Equecabtagene Autoleucel , Yujie Zhou , Innovent Biologics , Adimab Incyte , Incyte Corporation , University First Hospital , Anzhen Hospital Affiliated To Capital Medical University , Md Anderson Cancer Center , Zhongshan Hospital Affiliated To Fudan University , China National Medical Products Administration , China Cardiovascular Health , Clinical Development Of Innovent , Prnewswire Innovent Biologics Inc , National Medical Products Administration , Zhongshan Hospital Affiliated , Fudan University , Peking University First Hospital , Beijing Anzhen Hospital Affiliated , Capital Medical University , Lei Qian , Vice President , Clinical Development , Cardiovascular Health , Disease Report , Tafolecimab Injection , Sintilimab Injection , Bevacizumab Injection , Adalimumab Injection , Rituximab Injection , Pemigatinib Oral Inhibitor , Ramucirumab Injection , Selpercatinib Capsules , Cancer Center , Mainland China , Week Randomized , Placebo Controlled Phase , Chinese Patients , Heterozygous Familial Hypercholesterolemia , Chinese Patients With Hypercholesterolemia ,